GENE ONLINE|News &
Opinion
Blog

2021-06-24| ChinaR&D

China’s Legend Biotech to Build a CAR-T Therapy Production Site in Belgium

by Tyler Chen
Share To

Fresh off completing a rolling submission for ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy co-developed with Janssen, China’s Legend Biotech, has announced plans to establish a manufacturing facility in Belgium to boost the production of cilta-cel once it’s FDA approved.

 

Third Plant for Legend Biotech, a First in Europe

The Belgium facility is going to be the first plant in Europe and the third for Legend Biotech on top of the two in Nanjing, China, and New Jersey, US. For now, details of the plant remain unclear, but the site is expected to go into operation by 2023 and focus on manufacturing cell therapy products.

Also, it would put Legend Biotech in a better position to tap the local talent pool and support global supply as soon as cilta-cel gets approved.

 

Collaboration with Janssen

Janssen started working with Legend Biotech on developing CAR-T therapy at the end of 2017. The drug is developed for patients with relapsed/refractory multiple myeloma. It received a Breakthrough Therapy Designation (BTD) in the US in December 2019 and also got priority review in May 2021, meaning the FDA will make the decision by November 29th. What’s more, it’s the first CAR-T therapy accepted for review by the China Food and Drug Administration (CFDA).

 

Approved CAR-T Therapies

If approved, cilta-cel will be the second CAR-T therapy to treat those with relapsed/refractory multiple myeloma as BMS and bluebird bio won the race in March with Abecma, entering the market as the fifth CAR-T therapy and the first for the indication.

Currently, the US FDA has approved five CAR-T therapies, including Abecma and Breyanzi by BMS, Tecartus and Yescarta by Gilead, and Kymriah by Novartis.

Related Article: From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Mesoblast’s Resubmission Brings First-of-its-Kind Therapy One Step Closer to Approval
2023-03-09
Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration
2023-03-08
Developments in Regenerative Medicine: Gene Delivery Tools and Cell Therapy for Parkinson’s Disease
2023-03-08
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top